Lonza

View our recent webinar: Accelerating GMP QC testing of mRNA Therapeutics - based on next generation sequencing and machine learning In this on-demand presentation Amanda Hughes (Associate Principal Scientist) explores how combining next generation sequencing with machine learning can accelerate QC workflows while maintaining GMP demands. View today: https://lnkd.in/dnDfi9_2

🚀 The second edition of Specialized Modalities in Focus is now available.   This quarter, we explore a key industry trend: the transition from therapeutic promise to commercial reality. Discover insights on innovative mRNA analytical solutions, scalable AAV manufacturing platforms, evolving 𝘪𝘯 𝘷𝘪𝘷𝘰 delivery approaches, and commercial gene therapy supply. Explore how developers are addressing the manufacturing, quality, and scalability challenges shaping the next generation of advanced therapies.   You'll also find the latest industry news, expert insights, articles featured in leading publications, and upcoming events and webinars across cell & gene therapies, mRNA, viral vectors, and other emerging specialized modalities.   👉 Follow the newsletter to stay informed on the trends, technologies and manufacturing strategies shaping specialized modalities. If you find it valuable, please share it with your network and help grow our community.   🔗 Subscribe now: https://lnkd.in/d8x-68sz   #SpecializedModalities #CellAndGeneTherapy #mRNA #ViralVectors #AdvancedTherapies #CDMO    

Bioconjugate development is full of promise—but early decisions can significantly impact success. In this video interview, Nina Hentzen, Head of Preclinical Development Bioconjugates at Lonza, shares how early CMC insight, smart technology selection, and integrated development strategies can help reduce risk, accelerate timelines, and create a smoother path to manufacturing. By partnering early, developers can build stronger foundations for scalable, manufacturable bioconjugates from the start. 🎥 Watch the video to learn how Lonza helps transform promising molecules into development-ready therapies, and contact us if you want to discuss with our SMEs: https://ow.ly/nJYi50Zt4TO #Bioconjugates #ADC #DrugDevelopment #CDMO #EarlyDevelopment

View our recent webinar: What It Takes to Scale: Scaling Microbial Early Decisions into Commercial Readiness In this on-demand webinar Laura Bailey (Director, Program Management) explores how early microbial development decisions shape success at commercial scale. Overviewing: ✔ 5 proven scale-up principles ✔ How to avoid tech transfer & late-stage surprises ✔ Building robust, scalable processes from day one View today: https://lnkd.in/eqtZP7ni

We are proud to see the publication of our colleagues' latest open-access review in AAPS PharmSciTech: "Antibody–Drug Conjugates Drug Product Formulation and Process Development, Scalability and Stability Considerations." This work highlights the power of collaboration across Lonza's Bioconjugates and Drug Product Development teams, showcasing the end-to-end expertise customers need to successfully develop and manufacture ADCs. Congratulations to Orla McGarvey, Nils Hillebrandt, David Schmitt, Mamiko Ninomiya, Arundhati Chattopadhyay and Lea Sorret for their scientific leadership and contributions to this important publication. Advancing science is important—but translating expertise into customer value is what makes the difference. 📖 Read the full article: https://lnkd.in/eEVADfiY #ADC #DrugDevelopment #Bioconjugates #CDMO #Innovation #OneLonza

Join our upcoming panel discussion: Transitioning to AAV Producer Cell Lines – Navigating Comparability, Bridging Studies, and Regulatory Risk As AAV gene therapies advance toward broader indications, scalable and robust manufacturing is becoming increasingly important. But how do you successfully transition from transient transfection to a producer cell line platform while managing comparability and regulatory risk? Join our industry experts on 29 July | 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST to explore: ✅ Comparability requirements for PCL transitions ✅ When bridging studies may be required ✅ Regulatory considerations and development risk ✅ Strategies to support scalable, cost-efficient AAV manufacturing Learn practical approaches to adopting producer cell line technologies and building a more consistent, scalable AAV manufacturing process. Register today and secure your spot: https://lnkd.in/ejziqr5B Featuring Lonza experts: Laura Sands Head of Regulatory Affairs Suparna Sanyal, PhD Director of Commercial Development for Viral Vectors Ramesh Koukuntla, PhD Director of R&D Wenling Dong Head of Upstream Process Development Vijetha Bhat Subject Expert of Platform Technologies #AAV #GeneTherapy #CellAndGeneTherapy #AAVManufacturing #Bioprocessing #Biomanufacturing #CDMO #CMC #RegulatoryAffairs #Lonza

Today, we announced our Half-Year Results 2026, delivering sales of CHF 3.4 billion with +16.0% CER sales growth. CORE EBITDA reached CHF 1.2 billion, resulting in a margin of 34.8%, while Free Cash Flow improved to CHF 0.4 billion. Based on our strong H1 performance, we upgraded our Full-Year 2026 CORE EBITDA margin outlook to 33–34%, while maintaining our CER sales growth guidance of 11–12%. All three Business Platforms delivered double-digit CER sales growth, supported by sustained customer demand across technologies and geographies, continued momentum in strategic outsourcing activities and strong operational execution. We also expanded a strategic collaboration with a leading US biopharmaceutical company, reflecting the strength of our diversified business model and long-term customer partnerships. In addition, we announced the further expansion of our commercial-scale ADC drug product capacity in Stein (CH), backed by a long-term customer commitment. Read more about our Half-Year Results 2026 here: https://lnkd.in/eXXq8UH2 #CDMO #Lonza #Growth #PharmaceuticalManufacturing #Biotech

Today, we announced a licensing agreement with Engitix to help advance the development of next-generation antibody-drug conjugates (ADCs) for patients with chronic diseases. Through the agreement, Engitix will access Lonza’s clinically validated ADC technology platform, including our SYNtecan E™ linker-payload technology as well as GlycoConnect® and HydraSpace®. By combining these technologies with Engitix’s proprietary extracellular matrix (ECM) discovery platform, the collaboration aims to support the development of differentiated targeted therapies with the potential to address significant unmet patient needs. This collaboration highlights the power of combining cutting-edge science with proven ADC technologies to help accelerate the development of innovative therapies and unlock new possibilities in targeted treatment approaches. Read more: https://lnkd.in/eh7qvPJn #Lonza #CDMO #Bioconjugation #ADC #AdvancedSynthesis #Licensing

🚀 A new edition of Biologics in Focus is live, bringing you the latest insights, industry developments, and expert perspectives shaping the future of biologics development.   In this issue, we explore key themes emerging across the biologics landscape, including expanded manufacturing collaborations, innovative blood-brain barrier technologies, intensified fed-batch manufacturing, lessons from 70+ bispecific antibody programs, and strategies for de-risking early development.   We also look at how AI is beginning to influence biologics workflows as organizations seek to accelerate development while maintaining quality and scalability.   👉 Follow the newsletter to stay informed on the latest innovations, scientific advances, and practical insights across the biologics landscape.   If you find it valuable, please share it with your network and help grow our biologics community.   🔗 Subscribe to Biologics in Focus: https://lnkd.in/e9GgYKfk   #Lonza #CDMO #Biologics #BiologicsInFocus

Artificial intelligence is reshaping pharmaceutical development and manufacturing, creating new opportunities to accelerate timelines, enhance decision-making, and unlock greater efficiencies across the CDMO landscape. At BIO International Convention 2026, Dr. Zara Asgharpour, MBA, Head of External Innovation, Integrated Biologics, spoke with Patrick Lavery from Contract Pharma, about how AI and digital technologies are transforming biologics workflows and enabling more agile, data-driven approaches to development and manufacturing. Read the full article here: https://lnkd.in/enkbXbwb #Lonza #AI #Biologics #CDMO #Biopharma #DigitalTransformation #BIO2026 #DrugDevelopment